ATE525072T1 - Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen - Google Patents
Pyrazole zur behandlung von adipositas und anderen zns-erkrankungenInfo
- Publication number
- ATE525072T1 ATE525072T1 AT07749543T AT07749543T ATE525072T1 AT E525072 T1 ATE525072 T1 AT E525072T1 AT 07749543 T AT07749543 T AT 07749543T AT 07749543 T AT07749543 T AT 07749543T AT E525072 T1 ATE525072 T1 AT E525072T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazoles
- obesity
- treatment
- cns diseases
- cns
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77176806P | 2006-02-09 | 2006-02-09 | |
| PCT/US2007/002547 WO2007094962A2 (en) | 2006-02-09 | 2007-01-30 | Pyrazoles for the treatment of obesity and other cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525072T1 true ATE525072T1 (de) | 2011-10-15 |
Family
ID=38371978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07749543T ATE525072T1 (de) | 2006-02-09 | 2007-01-30 | Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7897634B2 (de) |
| EP (1) | EP1988777B1 (de) |
| JP (1) | JP5207983B2 (de) |
| AR (1) | AR059428A1 (de) |
| AT (1) | ATE525072T1 (de) |
| CA (1) | CA2641441A1 (de) |
| DK (1) | DK1988777T3 (de) |
| TW (1) | TWI386403B (de) |
| WO (1) | WO2007094962A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
| US20100113776A1 (en) * | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
| MX2009011787A (es) | 2007-05-03 | 2009-11-13 | Cephalon Inc | Procesos para preparar (r)-2-metilpirrolidina y (s)-2-metilpirrolidina y sales de tartrato de las mismas. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101855211B (zh) * | 2007-11-13 | 2013-06-12 | 大正制药株式会社 | 苯基吡唑衍生物 |
| JP5740838B2 (ja) * | 2009-05-12 | 2015-07-01 | 大正製薬株式会社 | フェニルピラゾール誘導体 |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| BR112014013461A2 (pt) | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
| WO2013100054A1 (ja) | 2011-12-27 | 2013-07-04 | 大正製薬株式会社 | フェニルトリアゾール誘導体 |
| HRP20221373T1 (hr) | 2014-03-07 | 2023-01-06 | Biocryst Pharmaceuticals, Inc. | Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi |
| US11189975B1 (en) | 2017-05-07 | 2021-11-30 | Jeffrey P. Baldwin | Powered wall plate |
| US11509102B1 (en) | 2017-05-07 | 2022-11-22 | Jeffrey P. Baldwin | Powered wall plate with plug prongs |
| US11778302B1 (en) | 2019-04-23 | 2023-10-03 | Titan3 Technology LLC | Electrical wall plate with movably positionable camera |
| US11489280B1 (en) | 2019-06-04 | 2022-11-01 | Jeffrey P. Baldwin | Powered wall plate with keyed interface |
| US12335593B2 (en) | 2020-12-30 | 2025-06-17 | Titan3 Technology LLC | Electrical receptacle with built-in camera |
| US11489323B1 (en) | 2021-02-05 | 2022-11-01 | Jeffrey P. Baldwin | Powered wall plate with adjustable plug prongs |
| US12327956B1 (en) | 2022-02-01 | 2025-06-10 | Titan3 Technology LLC | Two-part powered electrical wall plate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940418A (en) * | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| KR20020088406A (ko) * | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| EP1444207A2 (de) * | 2001-09-19 | 2004-08-11 | Pharmacia Corporation | Substituierte pyrazolylverbindungen zur behandlung von entzündungen |
| US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| EP1653949A4 (de) * | 2003-08-07 | 2009-04-22 | Merck & Co Inc | Pyrazol-carboxamide als hemmer von 11-beta-hydroxysteroid dehydrogenase-1 |
| WO2005037199A2 (en) * | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| US7838524B2 (en) * | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| DK1773345T3 (en) * | 2004-06-30 | 2014-03-24 | Athersys Inc | NON-imidazol-tertiary amines AS HISTAMINE-3 receptor inhibitors in treating cognitive disorders, sleep disorders, obesity and other CNS DISORDERS |
| WO2007073405A1 (en) * | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| US8115005B2 (en) * | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
-
2007
- 2007-01-30 DK DK07749543.0T patent/DK1988777T3/da active
- 2007-01-30 US US11/699,662 patent/US7897634B2/en not_active Expired - Fee Related
- 2007-01-30 AT AT07749543T patent/ATE525072T1/de not_active IP Right Cessation
- 2007-01-30 JP JP2008554271A patent/JP5207983B2/ja not_active Expired - Fee Related
- 2007-01-30 WO PCT/US2007/002547 patent/WO2007094962A2/en not_active Ceased
- 2007-01-30 EP EP07749543A patent/EP1988777B1/de not_active Not-in-force
- 2007-01-30 CA CA002641441A patent/CA2641441A1/en not_active Abandoned
- 2007-02-09 TW TW096104902A patent/TWI386403B/zh not_active IP Right Cessation
- 2007-02-09 AR ARP070100559A patent/AR059428A1/es unknown
-
2011
- 2011-01-13 US US13/006,161 patent/US7981896B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI386403B (zh) | 2013-02-21 |
| DK1988777T3 (da) | 2012-01-16 |
| US7897634B2 (en) | 2011-03-01 |
| WO2007094962A2 (en) | 2007-08-23 |
| WO2007094962A3 (en) | 2008-01-31 |
| CA2641441A1 (en) | 2007-08-23 |
| EP1988777A4 (de) | 2010-08-25 |
| EP1988777B1 (de) | 2011-09-21 |
| US7981896B2 (en) | 2011-07-19 |
| US20110112088A1 (en) | 2011-05-12 |
| US20070197526A1 (en) | 2007-08-23 |
| EP1988777A2 (de) | 2008-11-12 |
| JP2009526054A (ja) | 2009-07-16 |
| AR059428A1 (es) | 2008-04-09 |
| JP5207983B2 (ja) | 2013-06-12 |
| TW200745092A (en) | 2007-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
| ATE512948T1 (de) | Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen | |
| EP1988777A4 (de) | Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen | |
| EP1981526A4 (de) | Adiponectin zur behandlung verschiedener erkrankungen | |
| DE112008000881A5 (de) | Medizinprodukt zur Behandlung von Verschlüssen von Körperdurchgängen und zur Prävention drohender Wiederverschlüsse | |
| EP2300035A4 (de) | Gemischte agonisten auf gip-basis zur behandlung von stoffwechselerkrankungen und fettsucht | |
| EP2240134C0 (de) | Verfahren und instrumente zur behandlung von adipositas und gastroösophagealem reflux | |
| EP2118300A4 (de) | Verhinderung und behandlung synukleinopathischer und amyloidogener krankheiten | |
| EP2278999C0 (de) | Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden | |
| SI2084151T1 (sl) | Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni | |
| DK2200616T3 (da) | Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi | |
| EP2007393A4 (de) | Thiazol- und thiophen-analoga sowie ihre verwendung zur behandlung von autoimmunerkrankungen und karzinomen | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
| ATE537150T1 (de) | Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate | |
| ATE429218T1 (de) | Pinolensäure zur behandlung von übergewicht | |
| IL196202A0 (en) | Indazole derivatives for the treatment of hsp90-induced diseases | |
| EP2135858A4 (de) | Zusammensetzung zur behandlung von infektionserkrankungen | |
| ATE448219T1 (de) | Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen | |
| ATE495179T1 (de) | Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen | |
| EP3769718C0 (de) | Vorrichtung zur behandlung von darmerkrankungen | |
| EP2217238A4 (de) | Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| DE602007011398D1 (de) | Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |